We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Peripheral Blood Smear Confirms Leishmaniasis

By LabMedica International staff writers
Posted on 05 Mar 2012
Peripheral buffy coat blood smears are a minimally invasive technique to diagnose the presence of the causative agents of visceral leishmaniasis (VL). More...


Buffy coat is the portion of blood that contains concentrates of white blood cells, including monocytes and platelets, and a smear can be examined for detection of amastigotes in suspected VL patients.

Laboratory staff at Rajshahi Medical College (Bangladesh) enrolled 112 VL patients in a prospective study during June 2009 to June 2010. Splenic aspiration was carried out for 66 patients by an experienced physician. The buffy coat was separated from the other blood components following the principle of concentration gradient separation by using Histopaque solution. Two good-quality smears prepared from buffy coat and stained with Leishman stain were examined under an oil immersion light microscope. Buffy coat DNA was extracted for a nested polymerase chain reaction (PCR) using the QIAamp DNA Blood Mini Kit.

The results of the study showed that 92% (103/112), 95.5% (107/112), and 100% (66/66) of VL patients were positive by buffy coat microscopy, buffy coat PCR, and spleen smear microscopy, respectively. Leishmania amastigotes were found by buffy coat microscopy in 93.5% (100/107) of those positive by buffy coat PCR and in 92.4% (61/66) of those positive for Leishmania amastigotes by spleen smear microscopy. Compared to spleen smear microscopy, the positivity rates of buffy coat PCR and buffy coat microscopy was comparable.

The buffy coat was prepared on Histopaque-1119 (Sigma-Aldrich, St. Louis, MO, USA) and the DNA extraction kit was from Qiagen (Hilden, Germany) The authors concluded that buffy coat smear was a promising confirmatory diagnostic tool for VL which can be used for point-of-care diagnosis in resource-limited health facilities. Splenic aspiration confirmation is risky and requires skilled personnel, and hence they are unavailable to the poor people in the regions of endemicity. Visceral leishmaniasis or Indian Kala-Azar is a vector-borne parasitic disease caused by an obligate intracellular hemoflagellate of the genus Leishmania and is fatal if it is not adequately treated. There are an estimated 500,000 new cases and 75,000 to 80,000 deaths per year, worldwide. The study was published in March 2012, in the Journal of Clinical Microbiology.

Related Links:
Rajshahi Medical College
Sigma-Aldrich
Qiagen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.